-- U.S. RESEARCH ROUNDUP-Centene, Las Vegas Sands, Guess
-- 
-- Mon Dec 15, 2014 12:10AM EST
-- None



Dec 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S. companies, including CB&I and MGM Resorts, on Monday.

HIGHLIGHTS * CB&I <CBI.N>: Stifel cuts to hold from buy * Centene Corp <CNC.N>: Susquehanna raises target price to $119 from $112; rating positive * Las Vegas Sands <LVS.N>: Stifel cuts target price to $75 from $80; rating buy   Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.* Alnylam Pharma <ALNY.O>: Leerink raises target price to $125 from $105; rating outperform * ARM Holdings <ARMH.O>: Canaccord Genuity raises target price to $56 from $54; rating buy * CB&I <CBI.N>: Stifel cuts to hold from buy * Centene Corp <CNC.N>: Susquehanna raises target price to $119 from $112; rating positive * Fluor Corp <FLR.N>: Stifel cuts target price to $68 from $86; rating buy * Guess Inc <GES.N>: Susquehanna cuts target price to $22 from $25; rating neutral * Jacobs Engineering <JEC.N>: Stifel cuts target price to $56 from $67; rating buy * Kirby Corp <KEX.N>: Macquarie cuts target price to $100 from $122; rating outperform * Kite Pharma <KITE.O>: Stifel raises target price to $71 from $45; rating buy * Las Vegas Sands <LVS.N>: Stifel cuts target price to $75 from $80; rating buy * Medivation Inc <MDVN.O>: UBS raises target price to $125 from $110; rating buy * MGM Resorts International <MGM.N>: Stifel cuts target price to $28 from $32; rating buy * Nevro Corp <NVRO.N>: Leerink raises target price to $40 from $35; rating outperform